Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Hansell H, Stedman"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 62-71 (2017)
Duchenne muscular dystrophy (DMD) is a lethal, X-linked, muscle-wasting disorder caused by mutations in the large, 2.4-Mb dystrophin gene. The majority of DMD-causing mutations are sporadic, multi-exon, frameshifting deletions, with the potential for
Externí odkaz:
https://doaj.org/article/baaed901fbc14b398a47c288c15dcfd1
Autor:
Hansell H. Stedman
Publikováno v:
Molecular Therapy. 31:1191-1192
Publikováno v:
Cell and Gene Therapy Insights. 6:569-575
Autor:
Jean Bennett, Kendall A. Lundgreen, Elisia D. Tichy, Shangzhen Zhou, Christopher D. Greer, Chomistek Sj, Leon Morales, Hansell H. Stedman, Carpenter Lj, Albert M. Maguire, Bailey Rj, Hoffman Jg, Gordon Gs, Bridges Cr, Kasden Cm, Jorge E. Osorio, Philip Hicks, Tabin Gc, Luo A, Benjamin W. Kozyak, Paul Bates, Salas-Quinchucua C
Prevention of COVID-19 is widely believed to depend on neutralization of SARS-CoV-2 by vaccine-induced humoral immunity1,2, raising concern that emerging escape variants may perpetuate the pandemic3–6. Here we show that a single intramuscular injec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0480011884baf2b9a13556cf4b8701b8
https://doi.org/10.1101/2021.08.16.456441
https://doi.org/10.1101/2021.08.16.456441
Publikováno v:
Molecular Therapy
Autor:
Kathleen J. Propert, Xiangping Lu, Margaret E Choi, Frederick J. Balzer, Shira T. Rosenblum, Daniel J VanBelzen, Leonard T. Su, Peter P. Nghiem, Joe N. Kornegay, Marilyn A. Mitchell, Mihail Petrov, Shangzhen Zhou, Benjamin W. Kozyak, Christopher D. Greer, Alock Malik, Yafeng Song, Andrew F. Mead, Ranjith K Krishnankutty, Robert A. French, Hansell H. Stedman, Emanuele Loro, Leon Morales, Tejvir S. Khurana
Publikováno v:
Nature Medicine. 25:1505-1511
The essential product of the Duchenne muscular dystrophy (DMD) gene is dystrophin1, a rod-like protein2 that protects striated myocytes from contraction-induced injury3,4. Dystrophin-related protein (or utrophin) retains most of the structural and pr
Publikováno v:
Mol Ther
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 62-71 (2017)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Duchenne muscular dystrophy (DMD) is a lethal, X-linked, muscle-wasting disorder caused by mutations in the large, 2.4-Mb dystrophin gene. The majority of DMD-causing mutations are sporadic, multi-exon, frameshifting deletions, with the potential for
Autor:
Yafeng, Song, Leon, Morales, Alock S, Malik, Andrew F, Mead, Christopher D, Greer, Marilyn A, Mitchell, Mihail T, Petrov, Leonard T, Su, Margaret E, Choi, Shira T, Rosenblum, Xiangping, Lu, Daniel J, VanBelzen, Ranjith K, Krishnankutty, Frederick J, Balzer, Emanuele, Loro, Robert, French, Kathleen J, Propert, Shangzhen, Zhou, Benjamin W, Kozyak, Peter P, Nghiem, Tejvir S, Khurana, Joe N, Kornegay, Hansell H, Stedman
Publikováno v:
Mol Ther
The essential product of the Duchenne muscular dystrophy (DMD) gene is dystrophin
Autor:
Valder R. Arruda, Timothy C. Nichols, Margaret H Whitford, Mark A. Kay, Hansell H. Stedman, Katherine A. High
Publikováno v:
Human Gene Therapy Clinical Development. 26:5-14
Preclinical testing of new therapeutic strategies in relevant animal models is an essential part of drug development. The choice of animal models of disease that are used in these studies is driven by the strength of the translational data for inform